期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

PAR-2在人胰腺癌细胞中的表达及吉西他滨的干预作用 被引量：1

下载PDF
导出
摘要 目的通过研究蛋白酶激活受体-2(proteinase activated receptor-2,PAR-2)在人胰腺癌细胞中的表达态势,明确PAR-2在胰腺癌中的表达特点,并通过RT-PCR观察吉西他滨对胰腺癌细胞中PAR-2 mRNA表达的影响。方法培养人胰腺癌细胞,收集人正常胰腺组织;设立五组:cancer组(胰腺癌细胞阳性对照组)、Gao组(吉西他滨给药浓度50μg/ml干预胰腺癌细胞)、Zhong组(吉西他滨给药浓度5μg/ml干预胰腺癌细胞)、Di组(吉西他滨给药浓度0.5μg/ml干预胰腺癌细胞)及normal组(正常胰腺组织阴性对照组)。RT-PCR实验观察各组PAR-2 mRNA的相对表达量。结果以Quantity one分析软件对实验结果进行分析,试验重复3次。cancer组、Di组、Zhong组、Gao组中细胞PAR-2 mRNA的相对表达量均高于normal组(P<0.001)c,ancer组>Di组、Zhong组、Gao组>normal组;但是Gao组、Zhong组、Di组三组间的相对表达量无显著性差异(P>0.05)。结论 PAR-2 mRNA在胰腺癌细胞高表达,胰腺癌的发生与发展与PAR-2正相关。吉西他滨能够降低胰腺癌细胞PAR-2 mRNA的表达率,可能是吉西他滨治疗胰腺癌的作用机制之一,但本实验未发现吉西他滨对PAR-2 mRNA表达的干预作用与剂量有关。
作者 刘星 胡煜辉 肖游章 张晓春 周青 徐建华 肖凤 罗友根 李晓飞
机构地区 武汉大学医学部公共卫生学院 井冈山大学医学院重点实验室 南昌市第二医院微创外科 吉安市中心人民医院手术室
出处 《中国老年学杂志》 CAS CSCD 北大核心 2011年第15期2893-2895,共3页 Chinese Journal of Gerontology
基金 吉安市科技局2010年度指导性科技计划项目 井冈山大学2010年校级自然科学科研项目(No.JZ10022)
关键词 胰腺癌 蛋白酶激活受体-2 吉西他滨 RT-PCR 剂量 相对表达量
分类号 R735.9 [医药卫生—肿瘤] R73-3 [医药卫生—肿瘤]
  • 相关文献

参考文献2

  • 1Kazuno H,Sakamoto K,Fujioka A,et al.Possible antitumor activity of 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine(ECyd,TAS-106)against an established gemcitabine(dFdCyd)-resistant human pancreat-ic cancer cell line〔J〕. Cancer Science . 2005
  • 2海鸥,谢立群,李轩,郑艳敏,周静.蛋白酶激活受体-2在原发性肝癌组织中的表达[J].世界华人消化杂志,2010,18(20):2159-2162. 被引量：5

二级参考文献12

  • 1胡红心,周红,王婷.蛋白酶激活受体1和2在结肠癌细胞的表达及其作用初探[J].江苏大学学报（医学版）,2007,17(1):23-27. 被引量：11
  • 2Kawabata A. [Physiological functions of protease- activated receptor-2] Nippon Yakurigaku Zasshi 2003; 121:411-420.
  • 3Cottrell GS, Amadesi S, Schmidlin F, Bunnett N. Protease-activated receptor 2: activation, signalling and function. Biochem Soc Trans 2003; 31:1191-1197.
  • 4Vergnolle N. Clinical relevance of proteinase activated receptors (pars) in the gut. Gut 2005; 54: 867-874.
  • 5Steinhoff M, Buddenkotte J, Shpacovitch V, Rattenholl A, Moormann C, Vergnolle N, Luger TA, Hollenberg MD. Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response. Endocr Rev 2005; 26: 1-43.
  • 6Ossovskaya VS, Bunnett NW. Protease-activated receptors: contribution to physiology and disease. Physiol Rev 2004; 84:579-621.
  • 7Jahan I, Fujimoto J, Alam SM, Sato E, Sakaguchi H, Tamaya T. Role of protease activated receptor-2 in tumor advancement of ovarian cancers. Ann Oncol 2007; 18:1506-1512.
  • 8Caruso R, Pallone F, Fina D, Gioia V, Peluso I, Caprioli F, Stolfi C, Perfetti A, Spagnoli LG, Palmieri G, Macdonald TT, Monteleone G. Protease- activated receptor-2 activation in gastric cancer cells promotes epidermal growth factor receptor transactivation and proliferation. Am J Pathol 2006; 169: 268-278.
  • 9DeFea KA, Zalevsky J, Thoma MS, Dery O, Mullins RD, Bunnett NW. beta-arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2. J Cell Biol 2000; 148:1267-1281.
  • 10van der Merwe JQ, Moreau F, MacNaughton WK. Protease-activated receptor-2 stimulates intestinal epithelial chloride transport through activation of PLC and selective PKC isoforms. Am J Physiol Gastrointest Liver Physiol 2009; 296:G1258-G1266.

共引文献4

同被引文献16

  • 1Shankar S, Marsh L, Srivastava RK. EGCG inhibits growth of human pancreatic tumors orthotopically implanted in BALB/c nude mice through modulation of FKHRL1/FOXO3a and neuropilin [ J]. Mol Cell Biochem, 2013, 372(1/2) : 83 -94.
  • 2Cavet ME, Harrington KL, Vollmer TR, et al. Anti-inflammatory and anti-oxidative effects of the green tea polyphenol epigallocatechin gallate in human corneal epithelial cells [ J ]. Mol Vis, 2011, 17: 533 - 542.
  • 3Du GJ, Zhang Z, Wen XD, et al. Epigallocatechin gallate (EGCG) is the most effective cancer chemopreventive polyphenol in green tea [J]. Nutrients, 2012, 4(11): 1679-1691.
  • 4Cai Y, Kurita-Ochiai T, Hashizume T, et al. Green tea epigalloeatechin-3- ll,te attenuates porphyromonas gingivalis-induced atheresclcrosis [ J ]. Pathog Dis, 2013,67(1) : 76 -83.
  • 5Qanungo S, Das M, Haldar S, et al. Epigallocatechin-3-gallate induces mitochondrial membrane depolarization and caspase-dependent apoptosis in pancreatic cancer cells [ J ]. Carcinogenesis, 2005, 26(5) : 958 -967.
  • 6Takada M, Nakamura Y, Koizumi T, et al. Suppression of human pancreatic carcinoma cell growth and invasion by epigallocatechin-3- gallate[J]. Pancreas, 2002, 25(1): 45-48.
  • 7Gong D J, Zhang JM, Yu M, et al. Inhibition of SIRT1 combined with gemcitabine therapy for pancreatic carcinoma [ J/OL]. Clin Interv Aging, 2013, 8:889-897.
  • 8Eckardt MA, Bean A, Selch MT, et al. A child with gemcitabine- induced severe radiation recall myositis resulting in a compartment syndrome[J]. J Pediatr Hematol Oncol, 2013, 35(2) : 156 -161.
  • 9Wato M, Inaba T, Ishikawa H, et al. A case of hemolytic uremic syndrome after adjuvant chemotherapy with gemcitabine in a patient with pancreatic cancer[ J]. Nihon Shokakibyo Gakkai Zasshi, 2010, 107 (10) : 1676 - 1685.
  • 10Nystedt S, Larsson AK, Aberg H, et al. The mouse proteinase-activated receptor-2 cDNA and gene. Molecular cloning and functional expression[ J/OA ]. J Biol Chem, 1995, 270 ( 11 ) : 5950 - 5955.

引证文献1

二级引证文献1

中国老年学杂志
2011年 第15期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部